US regulators on Friday approved AbbVie Incs new multidrug regimen for hepatitis C the latest in a wave of new medicines that is transforming treatment of the liver disease The US Food and Drug Administration approved AbbVies Viekira Pak an alloral cocktail of several drugs that cured more than  of people with the most common subtype of hepatitis C in the US genotype  in clinical trials The regimen consists of several pills taken daily for about  weeks for most patients eliminating the need for an older
  